The European Medicines Agency has agreed to fast-track its assessment of Sanofi’s sleeping sickness drug, fexinidazole, once the company submits a marketing authorization application for the product.
The EMA’s key scientific committee, the CHMP, decided last week that fexinidazole would be reviewed under its accelerated assessment procedure,...